Ferrell PB Jr, McLeod HL (2008) Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations
Until there is evidence from high-quality postmarketing studies, the FDA should consider updating labeling to advise caution on generalizing the safety and effectiveness of GLP-1 and GLP-1/GIP to populations excluded from pivotal trials. Limitations to wider generalizability of these findings are the self-reported nature of the participants medical conditions and the investigators inability to accurately measure all exclusion criteria, which lends itself to potential for underestimation
Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma
Novos dual agonist Wegovy works by stimulating a metabolic hormone called GLP-1, while Zepbound targets GLP-1 and a second one called GIP
This personalized pacing is key to long-term adherence
Using distilled water (9 ml), three samples of each QTLN formulation (1 ml) were diluted to assess the particle size and PDI in three replicates using dynamic light scattering (DLS, Malvern, Germany)